Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
ANVS - Annovis Bio Inc
$9.98
0.07(0.71%)9:00:00 PM 1/20/2021
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Stock Chart

Summary:

  • RSI is at a high level of 79. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Stock news

    01/5/2021ANVS
    Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference

    Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) -  Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the reg...

    12/17/2020ANVS
    Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report

    BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the ex...

    12/15/2020ANVS
    Annovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences

    BERWYN, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., presented her paper, “Targeting Increased Levels of Neurotoxic Proteins in Down Syndrome, Alzheimer’s and Parkinson’s Animals Normalized Axonal Transport, Cognition and Function,” at the New York Academy of Sciences’ Alzhei...

    12/7/2020ANVS
    Annovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020

    BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET. Investors interested in viewing Annovis Bio's presentation may register with free access here for the two-day conf...

    12/3/2020ANVS
    Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference

    BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020. Dr. Maccecchini’s presentation, “Targeting Increased Levels o...

    11/27/2020ANVS
    Here is What Hedge Funds Think About Annovis Bio, Inc. (ANVS)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

    11/16/2020ANVS
    Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium

    BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020.  Dr. Maccecchini and Mr. McGroarty will host virtual one-on-one meetings with investors to discuss...

    11/12/2020ANVS
    Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

    BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects. The nine-month dog study was part of a series of animal toxicology studies, f...